Oppenheimer Names Cepheid on December's Top Ideas

A report from Oppenheimer reiterates its Outperform rating on Cepheid CPHD. The report states, “Cepheid is a pure play molecular diagnostic company with a pioneering technology platform. The company provides a fully integrated, random access, scalable, molecular diagnostic solution for a variety of disease states. The GeneXpert platform has a very easy-to-use interface and can produce results in as little as one hour with approximately two minutes of prep time by the technician.” CPHD closed Friday at $31.48.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: Analyst ColorAnalyst RatingsDecember Top IdeasOppenheimer
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!